ACLX240517P50000
- 2.90
- 0.000.00%
Arcellx Newsroom
Gilead (GILD.US) /ArcellX's Next-Generation BCMA CAR-T Launches Phase III Clinical Trial
Gilead (GILD.US) and ArcellX registered a phase III clinical trial of Anitocabtagene Autoleucel for the treatment of recurrent or refractory multiple myeloma on the ClinicalTrials.gov website.
Arcellx Is Maintained at Buy by Stifel
Arcellx Is Maintained at Buy by Stifel
Express News | Arcellx Inc : Stifel Raises Target Price to $83 From $82
Truist Financial Reaffirms Their Buy Rating on Arcellx Inc (ACLX)
Analyst Expectations For Arcellx's Future
During the last three months, 14 analysts shared their evaluations of Arcellx (NASDAQ:ACLX), revealing diverse outlooks from bullish to bearish.The following table summarizes their recent ratings, she
Arcellx Initiated at Outperform by Evercore ISI Group
Arcellx Initiated at Outperform by Evercore ISI Group
Buy Rating for Arcellx Inc. on Promising CAR-T Cell Therapy Trials and Strategic Market Positioning
Express News | Arcellx Inc : Evercore ISI Initiates Coverage With Outperform Rating; Price Target $85
Arcellx Is Maintained at Buy by HC Wainwright & Co.
Arcellx Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Arcellx, Lowers Price Target to $80
Buy Rating Affirmed for Arcellx Inc. Amidst Promising Trial Progress and Strategic Partnerships
Arcellx, Inc. (NASDAQ:ACLX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Arcellx, Inc. (NASDAQ:ACLX) just released its quarterly report and things are looking bullish. The results were impressive, with revenues of US$39m exceeding analyst forecasts by 90%, and statuto
Arcellx First Quarter 2024 Earnings: Beats Expectations
Express News | Needham Reiterates Buy on Arcellx, Maintains $81 Price Target
Arcellx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 64.42% Needham → $81 Reiterates Buy → Buy 05/07/2024 64.42% Needham → $81 Reiterates Buy → Buy
Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge
Express News | Arcellx Shares Are Trading Lower After the Company Reported Q1 Financial Results
Buy Rating Affirmed for Arcellx Inc on Robust IMMagine-3 Study Prospects and Efficient Manufacturing
Buy Rating Justified for Arcellx Inc. Amidst Progress in Anito-cel's Clinical Development and Regulatory Milestones
Express News | Arcellx, Inc. : H.c. Wainwright Cuts Target Price to $80 From $82